GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Cyclically Adjusted PS Ratio

Incyte (Incyte) Cyclically Adjusted PS Ratio : 4.97 (As of May. 19, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Incyte Cyclically Adjusted PS Ratio?

As of today (2024-05-19), Incyte's current share price is $57.10. Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $11.49. Incyte's Cyclically Adjusted PS Ratio for today is 4.97.

The historical rank and industry rank for Incyte's Cyclically Adjusted PS Ratio or its related term are showing as below:

INCY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.5   Med: 20.99   Max: 102.35
Current: 4.97

During the past years, Incyte's highest Cyclically Adjusted PS Ratio was 102.35. The lowest was 4.50. And the median was 20.99.

INCY's Cyclically Adjusted PS Ratio is ranked better than
52.94% of 510 companies
in the Biotechnology industry
Industry Median: 5.555 vs INCY: 4.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Incyte's adjusted revenue per share data for the three months ended in Mar. 2024 was $3.877. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $11.49 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Incyte Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Incyte's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Cyclically Adjusted PS Ratio Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.25 14.71 9.65 8.60 5.72

Incyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.39 6.09 5.43 5.72 4.96

Competitive Comparison of Incyte's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PS Ratio falls into.



Incyte Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Incyte's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=57.10/11.49
=4.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Incyte's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.877/131.7762*131.7762
=3.877

Current CPI (Mar. 2024) = 131.7762.

Incyte Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.593 100.560 0.777
201409 1.048 100.428 1.375
201412 0.730 99.070 0.971
201503 0.926 99.621 1.225
201506 0.874 100.684 1.144
201509 1.034 100.392 1.357
201512 1.123 99.792 1.483
201603 1.368 100.470 1.794
201606 1.276 101.688 1.654
201609 1.387 101.861 1.794
201612 1.672 101.863 2.163
201703 1.967 102.862 2.520
201706 1.591 103.349 2.029
201709 1.795 104.136 2.271
201712 2.104 104.011 2.666
201803 1.806 105.290 2.260
201806 2.424 106.317 3.004
201809 2.082 106.507 2.576
201812 2.446 105.998 3.041
201903 2.294 107.251 2.819
201906 2.437 108.070 2.972
201909 2.533 108.329 3.081
201912 2.652 108.420 3.223
202003 2.623 108.902 3.174
202006 3.121 108.767 3.781
202009 2.837 109.815 3.404
202012 3.601 109.897 4.318
202103 2.726 111.754 3.214
202106 3.175 114.631 3.650
202109 3.658 115.734 4.165
202112 3.887 117.630 4.354
202203 3.289 121.301 3.573
202206 4.075 125.017 4.295
202209 3.673 125.227 3.865
202212 4.120 125.222 4.336
202303 3.585 127.348 3.710
202306 4.231 128.729 4.331
202309 4.063 129.860 4.123
202312 4.475 129.419 4.556
202403 3.877 131.776 3.877

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incyte  (NAS:INCY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Incyte Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Incyte's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (Incyte) Business Description

Industry
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Steven H Stein officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Vijay K Iyengar officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Thomas Tray officer: Principal Accounting Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Sheila A. Denton officer: EVP & General Counsel 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Edmund Harrigan director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Paula J Swain other: Exec VP, Human Resources C/O INCYTE CORPORATION, 3160 PORTER DRIVE, PALO LATO CA 94304
Pablo J Cagnoni officer: President, R&D ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Maria E Pasquale officer: EVP & General Counsel C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Susanne Schaffert director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Barry P Flannelly officer: See Remarks ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Jonathan Elliott Dickinson officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Wendy L Dixon director